Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...